35969-51-8

Basic information

• Product Name: 2-(2-ETHOXY-2-OXOETHYL)NICOTINIC ACID
• Synonyms: 2-(2-ETHOXY-2-OXOETHYL)NICOTINIC ACID;2-(2-Ethoxy-2-oxoethyl)pyridine-3-carboxylic acid
• CAS NO: 35969-51-8
• Molecular Formula: C10H11NO4
• Molecular Weight: 209.2
• Mol File: 35969-51-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 134-136°C
• Boiling Point: 345.3 °C at 760 mmHg
• Flash Point: 162.6 °C
• Appearance: /
• Density: 1.271 g/cm³
• Vapor Pressure: 2.36E-05mmHg at 25°C
• Refractive Index: 1.543
• CAS DataBase Reference: 2-(2-ETHOXY-2-OXOETHYL)NICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-ETHOXY-2-OXOETHYL)NICOTINIC ACID(35969-51-8)
• EPA Substance Registry System: 2-(2-ETHOXY-2-OXOETHYL)NICOTINIC ACID(35969-51-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 35969-51-8(Hazardous Substances Data)

Usage

General Description

2-(2-ethoxy-2-oxoethyl)nicotinic acid is a chemical compound that belongs to the family of pyridine carboxylic acids. It is a derivative of nicotinic acid, also known as vitamin B3, and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and active pharmaceutical ingredients. 2-(2-ETHOXY-2-OXOETHYL)NICOTINIC ACID is known for its potential use in the treatment of various conditions, including cardiovascular diseases, metabolic disorders, and inflammation. It is also being studied for its potential antioxidant and neuroprotective properties. Its unique structure, which contains both a pyridine ring and an ethoxy-oxoethyl group, makes it a key intermediate in the synthesis of various bioactive compounds.

InChI:InChI=1/C10H11NO4/c1-2-15-9(12)6-8-7(10(13)14)4-3-5-11-8/h3-5H,2,6H2,1H3,(H,13,14)

Upstream product

• 2942-59-8 2-chloronicotinic acid 
• 141-97-9 ethyl acetoacetate 
• 67-63-0 isopropyl alcohol 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 3430-17-9 2-bromo-3-picoline 
• 35905-85-2 2-bromonicotinic acid 
• 105-53-3 diethyl malonate 

Downstream Products

• 399017-38-0 7-(3-carboxypyridin-2-yl)quinolizinium-1-carboxylate inner salt 
• 19693-54-0 6-Methyl-1,6-naphthyridin-5-(6H)-on 

Relevant articles and documents

MODULATORS OF HEMOGLOBIN

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin and methods for their use in treating disorders mediated by hemoglobin. (Formula (I))

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders

Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer's disease through upregulation of cyclic nucleotides in the brain and thereby achieve potentiation of cyclic nucleotide signaling pathways. This article details the expedited optimization of our recently disclosed pyrazolo[1,5-a]pyrimidine lead compound 4b, leading to the discovery of clinical candidate 36 (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration. Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochemical properties to deliver brain penetration. Oral administration of 36 demonstrated significant elevation of 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brains and improved cognitive performance in a novel object recognition task in rats. Consequently, compound 36 was advanced into human clinical trials.

SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.